Opinion|Videos|November 8, 2024
Management of Generalized Myasthenia Gravis in Pediatric Patients
Key Takeaways
- Diagnosing pediatric gMG is challenging due to its rarity and symptom overlap with other neuromuscular disorders, necessitating careful clinical evaluation.
- Standard management includes acetylcholinesterase inhibitors, corticosteroids, and immunosuppressants, customized to each patient's needs.
Panelists discuss how generalized myasthenia gravis (gMG) presents unique diagnostic challenges in pediatric populations, review current standard-of-care management strategies for children and adolescents, and highlight promising investigational treatments for pediatric gMG.
Advertisement
Video content above is prompted by the following:
- Generalized MG, although rare, can affect children and adolescents. What are the challenges in diagnosing this patient population?
- What is the standard of care for management of gMG in the pediatric population?
- Please highlight some investigational agents for pediatric gMG that you are excited about.
Advertisement
Related to this article
Alnylam Pharmaceuticals reported initial Phase 1b findings showing brezosiran reduced cerebrospinal fluid mutant huntingtin levels by a mean of 60% to 64% at 3 months, with plans for a pivotal study in 2027.
AL-S Pharma outlined the design of AP101-03, a planned phase 3 trial of AP-101 in sporadic and SOD1-associated ALS, at the 2026 NEALS Annual Meeting.
Sabirnetug failed to meet its primary endpoint in Acumen Pharmaceuticals' phase 2 ALTITUDE-AD trial for early Alzheimer disease, prompting the company to end development.
Pediatric epilepsy care goes beyond seizures, addressing mental health, learning needs, coordinated referrals, equitable access, and smoother transition to adult services.
The FDA accepted uniQure's biologics license application for ifezuntirgene inilparvovec and granted it Priority Review, setting a target action date of May 1, 2027.
Jeffrey Cohen, MD, professor of neurology and staff physician at the Cleveland Clinic Mellen Center for Multiple Sclerosis, discusses interim BREAKFREE-2 findings for zola-cel, a CD19-directed CAR T cell therapy, in relapsing and progressive MS.
Here's some of what is coming soon to NeurologyLive® this week.
Interim phase 1b/2a data showed all patients treated with high- or low-dose BB-301 for oculopharyngeal muscular dystrophy met formal response criteria.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Grants Priority Review to Huntington Disease Gene Therapy BLA
2
Zola-Cel and Treatment-Free Remission: What the BREAKFREE-2 Data Show
3
Examining Trontinemab in Early Alzheimer Disease: The Phase 3 TRONTIER 1 and 2 Trials
4
Understanding Cemdisiran's Mechanism of Action in Myasthenia Gravis
5